208 related articles for article (PubMed ID: 32886176)
1. Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents.
Nakai Y; Kanaki T; Yamamoto A; Tanaka R; Yamamoto Y; Nagahara A; Nakayama M; Kakimoto KI; Ishibashi M; Nishimura K
J Bone Miner Metab; 2021 Mar; 39(2):295-301. PubMed ID: 32886176
[TBL] [Abstract][Full Text] [Related]
2. Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) in urological malignancies: a multi-center retrospective study.
Sakai Y; Shindo T; Sato S; Takahashi A; Kunishima Y; Kato R; Itoh N; Okada M; Tachiki H; Taguchi K; Takayanagi A; Hotta H; Horita H; Matsukawa M; Matsuki M; Nishiyama K; Miyazaki A; Hashimoto K; Tanaka T; Masumori N
J Bone Miner Metab; 2021 Jul; 39(4):661-667. PubMed ID: 33704573
[TBL] [Abstract][Full Text] [Related]
3. [Risk Factors of Antiresorptive Agent-Related Osteonecrosis of the Jaw in Prostate Cancer Patients with Bone Metastases].
Ito K; Iijima H; Kumagai M; Yabusaki R; Muro Y; Shiraishi Y; Imamura M; Yoshimura K
Hinyokika Kiyo; 2023 May; 69(5):125-129. PubMed ID: 37312492
[TBL] [Abstract][Full Text] [Related]
4. [Incidence of Antiresorptive Agent-Related Osteonecrosis of the Jaw in Urologic Cancers].
Kawanishi H; Yokozeki H; Hoshiyama A; Watanabe H; Funahashi Y; Fujiwara M; Takashima Y; Shintani M; Yui S; Okumura K
Hinyokika Kiyo; 2022 Jan; 68(1):1-6. PubMed ID: 35114759
[TBL] [Abstract][Full Text] [Related]
5. Cumulative incidence and risk factors for medication-related osteonecrosis of the jaw during long-term prostate cancer management.
Tani M; Hatano K; Yoshimura A; Horibe Y; Liu Y; Sassi N; Oka T; Okuda Y; Yamamoto A; Uemura T; Yamamichi G; Ishizuya Y; Yamamoto Y; Kato T; Kawashima A; Nonomura N
Sci Rep; 2024 Jun; 14(1):13451. PubMed ID: 38862617
[TBL] [Abstract][Full Text] [Related]
6. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.
Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
Cancer Chemother Pharmacol; 2021 Jun; 87(6):871-877. PubMed ID: 33791853
[TBL] [Abstract][Full Text] [Related]
7. Anti-VEGFR therapy is one of the healing inhibitors of antiresorptive-related osteonecrosis of the jaw.
Kanno C; Kaneko T; Endo M; Kitabatake T; Sakuma T; Kanaya Y; Watanabe Y; Hasegawa H
J Bone Miner Metab; 2021 May; 39(3):423-429. PubMed ID: 33196901
[TBL] [Abstract][Full Text] [Related]
8. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.
Shibahara T
Tohoku J Exp Med; 2019 Feb; 247(2):75-86. PubMed ID: 30713280
[TBL] [Abstract][Full Text] [Related]
9. Single-center analysis of antiresorptive agent-related osteonecrosis of the jaw in lung cancer patients.
Okamura M; Fujita K; Yamamoto Y; Kanai O; Nakatani K; Horimoto K; Hashimoto M; Sawai S; Shimosato M; Yoshida K; Mio T
Asia Pac J Clin Oncol; 2020 Dec; 16(6):380-384. PubMed ID: 32893984
[TBL] [Abstract][Full Text] [Related]
10. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.
Ikesue H; Mouri M; Tomita H; Hirabatake M; Ikemura M; Muroi N; Yamamoto S; Takenobu T; Tomii K; Kawakita M; Katoh H; Ishikawa T; Yasui H; Hashida T
Support Care Cancer; 2021 Aug; 29(8):4763-4772. PubMed ID: 33527228
[TBL] [Abstract][Full Text] [Related]
11. Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?
Sidhu HK
Dent Update; 2015 Jun; 42(5):436-8, 440. PubMed ID: 26964445
[TBL] [Abstract][Full Text] [Related]
12. Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator-mandated cohort postauthorization safety study in Denmark, Norway, and Sweden.
Ehrenstein V; Heide-Jørgensen U; Schiødt M; Akre O; Herlofson BB; Hansen S; Larsson Wexell C; Nørholt SE; Tretli S; Kjellman A; Glennane A; Lowe KA; Sørensen HT
Cancer; 2021 Nov; 127(21):4050-4058. PubMed ID: 34310704
[TBL] [Abstract][Full Text] [Related]
13. Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis.
Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
Support Care Cancer; 2022 Mar; 30(3):2341-2348. PubMed ID: 34738163
[TBL] [Abstract][Full Text] [Related]
14. Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis.
Voss PJ; Steybe D; Poxleitner P; Schmelzeisen R; Munzenmayer C; Fuellgraf H; Stricker A; Semper-Hogg W
Odontology; 2018 Oct; 106(4):469-480. PubMed ID: 29713913
[TBL] [Abstract][Full Text] [Related]
15. Prognosis of medication-related osteonecrosis of the jaws in metastatic prostate cancer patients.
Wei LY; Kok SH; Lee YC; Chiu WY; Wang JJ; Cheng SJ; Chang HH; Lee JJ
Oral Dis; 2022 Jan; 28(1):182-192. PubMed ID: 33254278
[TBL] [Abstract][Full Text] [Related]
16. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for skeletal-related events in non-small cell lung cancer patients treated with bone-modifying agents.
Saito G; Ebata T; Ishiwata T; Iwasawa S; Yoshino I; Takiguchi Y; Tatsumi K
Support Care Cancer; 2021 Jul; 29(7):4081-4088. PubMed ID: 33404803
[TBL] [Abstract][Full Text] [Related]
18. Bone modifying agents for patients with bone metastases from breast cancer managed in routine practice setting: Treatment patterns and outcome.
Zekri J; Farag K; Yousof O; Zabani Y; Mohamed W; Ahmed GA
J Oncol Pharm Pract; 2020 Jun; 26(4):906-911. PubMed ID: 31575357
[TBL] [Abstract][Full Text] [Related]
19. Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials.
Jiang L; Cui X; Ma H; Tang X
J Orthop Surg Res; 2021 Jun; 16(1):400. PubMed ID: 34158101
[TBL] [Abstract][Full Text] [Related]
20. Synchronous antiresorptive osteonecrosis of the jaws and breast cancer metastasis.
Flores IL; dos Santos-Silva AR; Della Coletta R; Vargas PA; Lopes MA
Oral Surg Oral Med Oral Pathol Oral Radiol; 2014 Mar; 117(3):e264-8. PubMed ID: 24528798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]